Mesenchymal–epithelial transition gene (MET) exon 14 skipping mutations and MET amplification occur in approximately 3 ~ 4% [78–80] and 1 ~ 6% [81–83] of patients with NSCLC, respectively [84]. This evidence concerns the gene MET and non-small cell lung carcinoma.